ASH

Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.

Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.

This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.

Wojciech Jurczak MD PhD discusses research from ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is superior to bendamustine plus rituximab as initial therapy for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. The BRUIN CLL-313 phase 3 study found pirtobrutinib significantly improved progression-free survival and was well-tolerated. These data suggest pirtobrutinib could become a new standard of care for these patients.

This episode discusses how the bispecific antibody Epcoritamab, in combination with rituximab and lenalidomide, has outperformed standard treatment for relapsed/refractory follicular lymphoma in the phase three epcore FL-1 trial. Dr. Lorenzo Falchi, an attending physician at Memorial Sloan Kettering, was interviewed at the ASH 2025 Annual Meeting, where these significant findings, including improved ORR and PFS, were presented, demonstrating a substantial reduction in the risk of progression or

An interview with Amir Fathi MD from Massachusetts General Hospital discusses the Paradigm study presented at ASH 2025. The phase two randomized trial found that young, fit adults with acute myeloid leukemia had improved event-free survival and higher response rates with azacitidine/venetoclax initial therapy. This gentler treatment also led to fewer toxicities and better quality of life compared to standard induction chemotherapy.

Dr. Jennifer A. Woyach discusses promising phase III study findings at ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is as effective as ibrutinib, while demonstrating less toxicity, in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. This first randomized head-to-head comparison shows pirtobrutinib met its primary endpoint of non-inferiority for overall response rate.

Meletios Dimopoulos MD, Chair of Clinical Therapeutics at the University of Athens, discusses early findings from the phase 1b LINKER-MM2 trial presented at ASH 2025. The study reveals high clinical response rates for the B-Cell Maturation Antigen bispecific antibody linvoseltamab when combined with anti-CD38 therapy in patients with relapsed/refractory multiple myeloma. These preliminary safety and efficacy data support further development of this promising combination for MM treatment.

Antonio Jimenez Jimenez MD MS, from the University of Miami, presented findings at ASH 2025 indicating that donor choice is less of a barrier to allogeneic stem cell transplantation for patients with hematologic malignancies. The National Marrow Donor Program Access Trial found that post-transplant cyclophosphamide enables a wider, more ethnically diverse range of patients to safely receive transplants from unrelated donors.

Dr. Luciano Costa discusses the findings from the CARTITUDE-4 study at the ASH 2025 Annual Meeting in Orlando. The study demonstrates that ciltacabtagene autoleucel CAR-T cell therapy provides significant long-term progression-free survival for patients with standard-risk relapsed or refractory multiple myeloma, even as early as second-line treatment. The findings suggest profound benefits in this patient population.

Dr. Jesse Tettero discusses findings from the HARMONY Alliance study, presented at ASH 2025, validating measurable residual disease (MRD) as a robust predictor of overall survival in acute myeloid leukemia (AML) patients. The study supports MRD's potential as a regulatory surrogate endpoint, particularly MFC-MRD in non-transplanted patients, to accelerate drug development. This large pooled analysis provides critical evidence for future AML drug approvals.

Dr. Hisham Abdel-Azim discusses findings from the phase two EndRAD trial, presented at ASH 2025. The study reveals that Next Generation Sequencing-Assessed Minimum Residual Disease (NGS-MRD) can identify young patients with high-risk/relapsed B-cell Acute Lymphoblastic Lymphomas (B-ALL) who can safely omit pre-transplant Total Body Irradiation (TBI). This approach achieved comparable survival outcomes while potentially reducing TBI-associated late effects.

Financial Disaster from curative treatment for childhood ALL

Dramatic Cures for Children with No Prospects Using Standard Therapies for T-cell malignancies

Don't Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia

Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best p

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical

ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe

ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe

ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (V

ATLANTA—Adding anti-BCL-2 therapy with the small-molecule drug venetoclax (VEN) to standard low-dose cytarabine (LDAC) chemotherapy tripled response rates over historical comparators and extended surv

ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple m

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting

ATLANTA, GEORGIA—A “third generation” tyrosine kinase inhibitor — ponatinib — has succeeded in controlling chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia

ATLANTA, GEORGIA—Arsenic could play a key role in perfecting gentle but curative regimens for acute promyelocytic leukaemia, according to Italian researchers reporting to the 2012 American Society of

ATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of H

ATLANTA, GA—Solid confirmation of target hematocrit to minimise clotting risks in polycythemia vera has been presented at the American Society of Hematology annual meeting and simultaneously published

ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology ann

ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of t

ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology ann

ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study rep

ORLANDO—Primary mediastinal large B cell lymphoma responded excellently to a dose-dense schedule of R-CHOP immuno-chemotherapy followed by ICE chemotherapy — without the need for radiotherapy — in a s

Mary Eapen Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008 IN THIS EDITION: Greater Role for Umbilical Cord Blood

Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007

Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando) A

Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free surv

Christian Geisler CHRISTIAN GEISLER, Rigshospitalet, Copenhagen Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek T

Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid

Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase

Pierre Fenaux PIERRE FENAUX, Paris 13 University Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with

Jonathan Kolitz JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute For patients with acute myeloid leukemia in first remission, new data suggests tha

Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni

Zakari Aliyu REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta ZAKARI ALIYU, Howard University, Washington DC Nigeria has the highest incidence of sickle cell anemi

Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h

Martin Müller Charles Linker Andreas Hochhaus Christian Buske Katarina Le Blanc Stephen Emerson Alessandro Vannucchi Kanti Rai Richard Schlenk BCR-ABL Mutations After Imatinib Failure: Impact on Respo

Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncol

Reporting from: American Society of Hematology Meeting, Philadelphia, December 6-10, 2002 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Anton Hagenbeek, University of Utrec

Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therap

Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma

Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH

Reporting from: – American Society of Hematology 46th Annual Meeting, December 4-7, 2004, San Diego – San Antonio Breast Cancer Symposium, December 8-11, 2004 – Gastrointestinal Canc